Could an MS pill protect the brain in Alzheimer's? new trial launches
NCT ID NCT06639282
First seen Mar 11, 2026 · Last updated Jun 20, 2026 · Updated 24 times
Summary
This Phase II trial tests whether siponimod, a drug already approved for multiple sclerosis, can safely slow brain atrophy in people with mild Alzheimer's disease. Over 18 months, 105 participants will receive either the drug or a placebo. Researchers will measure brain volume changes, cognitive function, and biomarkers to see if the drug offers any benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
St. Joseph's Hospital and Medical Center
RECRUITINGPhoenix, Arizona, 85013, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
siponimod (Mayzent)
What this could lead to
If successful, this could point toward a new treatment that slows brain shrinkage and cognitive decline in early Alzheimer's disease.
What could go wrong
This is an early Phase II trial with only 105 participants, so results may not be conclusive. Siponimod also has known risks like infections and heart issues, and it is unclear if benefits seen in MS will translate to Alzheimer's.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.